Platinum Drugs
2012
-
C. F. Chin, Q. Tian, M. I. Setyawati, W. Fang, E. S. Q. Tan, D. T. Leong, W. H. Ang*,
Tuning the activity of platinum(IV) anticancer complexes through asymmetric acylation,
J. Med. Chem.,
2012,
55,
7571-7582
-
J. Li, S. Q. Yap, C. F. Chin, G. Pastorin*, W. H. Ang*,
Platinum(IV) prodrugs entrapped within multiwalled carbon nanotubes: Selective release by chemical reduction and hydrophobicity reversal,
Chem. Sci.,
2012,
3,
2083-2087
-
D. Y. Q. Wong, J. Y. Lau, W. H. Ang*,
Harnessing chemoselective imine ligation for tethering bioactive molecules to platinum(IV) prodrugs,
Dalton Trans.,
2012,
41,
6104-6111
2011
-
J. Li, S. Q. Yap, S. L. Yoong, T. R. Nayak, G. W. Chandra, W. H. Ang, T. Panczyk, S. Ramaprabhu, S. K. Vashist, F.-S. Sheu, A. Tan, G. Pastorin*,
Carbon nanotube bottles for incorporation, release and enhanced cytotoxic effect of cisplatin,
Carbon,
2011,
50,
1625-1634
-
C. F. Chin, D. Y. Q. Wong, R. Jothibasu, W. H. Ang*,
Platinum(IV) anticancer complex with novel modes of activity,
Curr. Op. Med. Chem.,
2011,
11,
2602-2612
-
G. Zhu, M. Myint, W. H. Ang, L. Song, S. J. Lippard*,
Monofunctional Platinum–DNA Adducts Are Strong Inhibitors of Transcription and Substrates for Nucleotide Excision Repair in Live Mammalian Cells,
Cancer Res.,
2011,
72,
790-800
-
K. Johansson, M. Ito, C. M. S. Schophuizen, S. Matthew, V. Heuser-Dahlström, J. Zhang, M. Shimoji, W. H. Ang, P. Dyson, A. Shibata, S. Shuto, Y. Ito, H. Abe, R. Morgenstern*,
Characterization of new potential anti-cancer drugs designed to overcome glutathione transferase mediated resistance,
Mol. Pharmacol.,
2011,
8,
1698-1708
-
N. Graf, W. H. Ang, G. Zhu, M. Myint, S. J. Lippard*,
Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity,
ChemBioChem,
2011,
12,
1115-1123
-
L. J. Parker, L. C. Italiano, C. J. Morton, N. C. Hancock, D. B. Ascher, J. B. Aitken, H. H. Harris, P. Campomanes, U. Rothlisberger, A. De Luca, M. Lo Bello, W. H. Ang, P. J. Dyson, M. W. Parker*,
Studies of glutathione transferase P1-1 bound to a platinum(IV)-based anticancer compound reveal the molecular basis of its activation,
Chem. Eur. J.,
2011,
17,
7806-7816
2009
-
W. H. Ang, S. J. Lippard*,
Functional consequence of plasmid DNA modified site-specifically with 7-deaza-deoxyadenosine at a single, programmable site,
Chem. Commun.,
2009,
5820-5822
-
W. H. Ang, W. W. Brown, S. J. Lippard*,
Preparation of platinated mammalian expression vectors incorporating site-specifically platinated-DNA lesions,
Bioconjugate Chem.,
2009,
20,
1058-1063
2007
-
C. Hartinger*, W. H. Ang, A. Casini, L. Messori, B. K. Keppler, P. J. Dyson,
Mass spectrometric analysis of ubiquitin-platinum complex interaction in leading anticancer drugs: MALDI versus ESI,
J. Anal. At. Spec.,
2007,
22,
960-967
2005
-
W. H. Ang, I. Khalaila, C. S. Allardyce, L. Juillerat-Jeanneret, P. J. Dyson*,
Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance,
J. Am. Chem. Soc.,
2005,
127,
1382-1383
-
W. H. Ang, S. Pilet, R. Scopelliti, F. Bussy, L. Juillerat-Jeanneret*, P. J. Dyson*,
Synthesis and characterization of platinum(IV) anticancer drugs with functionalized aromatic carboxylate ligands: Influence of the ligands on drug efficacies and uptake,
J. Med Chem.,
2005,
48,
8060-8069
